(CercleFinance.com) – Abionyx Pharma, a ‘biotech’ which focuses on the treatment of kidney and ophthalmological diseases, provided an update yesterday evening on its activity and its cash position in the 1st quarter.
After elimination of intra-group transactions, the company says it recorded a consolidated quarterly turnover of 1.2 million euros.
Abionyx specifies that it did not generate any revenue during the quarter concerning its activity devoted to the discovery and development of innovative therapies.
Its subsidiary Iris Pharma claims for its part a quarterly turnover of 1.6 million euros.
In its press release, the company recalls that beyond a cash position of nearly six million euros available and the total financing of phase 2a by the Italian consortium CBVF, no dilutive financial instrument has been put in place. square.
Following this publication, the Abionyx share changed little (-0.4%) on Friday on the Paris Stock Exchange.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
